In a bid to get full @US_FDA approval for the #Pfizer booster, Dr. Bill Gruber, Senior VP of Vaccine Clinical R&D, admits waning vaccine effectiveness, including hospitalizations.
W/out any finished trial data, the FDA approved the booster for people 65+ or at high risk.